Adiposs Raises CHF 4M to advance cancer imaging tool

01.07.2025 12:00, Rita Longobardi

Swiss life sciences company Adiposs has closed a CHF 4M Series A round to support clinical development of its imaging product for brown fat, aiming to improve early assessment of cancer treatment response.

Adiposs is developing ImageBAT®, a novel contrast agent that enables non-invasive CT imaging of brown adipose tissue—an early marker of treatment effectiveness. Current imaging methods cannot reliably detect this tissue.

Proceeds from the round will fund a proof-of-principle clinical trial. Regulatory approval has been granted, and the first subjects were dosed in June 2025. Top-line results are expected in the first quarter of 2026.

The financing was led by Swiss and Taiwanese venture firms, alongside European family offices and private investors. The Medtech company is also expanding its board to support the next stage of its growth.

By using standard CT imaging already available in hospitals, Adiposs aims to bring scalable innovation to oncology care. The startup has won Venture Kick, participated in Venture Leaders, and been ranked among the TOP 100 Swiss startups.

Adiposs team: CTO Nathalie Stransky, Co-Founder and Chief Development Officer Duc Tran, Chief Medical Officer Hervé Porchet, and Co-Founder and  CEO Andrej Babic